{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:46:27Z","timestamp":1772793987023,"version":"3.50.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl. 5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2314,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Treatment of patients with chronic hepatitis B virus (HBV) infection who have advanced disease or comorbidities can be challenging, and recommendations may differ from standard guidelines. Among the special populations that merit specific consideration are patients with compensated or decompensated cirrhosis, organ transplantation, acute hepatitis B, pregnancy, coinfection with hepatitis C and\/or D virus, chronic renal failure, and children. Major advances have been made in management of many of these special populations because of recent increasing availability of oral nucleosides, which are generally well tolerated and highly effective despite presence of other morbidities or viral infections. Also important have been changes in the management of hepatitis B during the peri-liver transplantation period that allows for prevention of reinfection in the majority of cases. However, much remains to be done to determine which patients should be treated and which should be monitored on no specific therapy. Outcomes of chronic HBV infection in persons with coinfection and in children have varied from different areas of the world, but it is not clear whether these differences are due to host and racial differences or to viral genotypic differences. Further studies are particularly needed in assessing the safety and efficacy of therapy in pregnant women, in children, and in patients with hepatitis D and C virus coinfection. (Hepatology 2009;49:S146\u2013S155.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22965","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T13:21:03Z","timestamp":1277385663000},"page":"S146-S155","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["Special populations with hepatitis B virus infection #"],"prefix":"10.1097","volume":"49","author":[{"given":"Marion G.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20241201","first-page":"690","article-title":"Chronic hepatitis: morphology and nomenclature.","volume":"7","author":"Ishak","year":"1994","journal-title":"Mod Pathol"},{"key":"R2-18-20241201","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","article-title":"Peginterferon alpha2b is safe and effective in HBeAgpositive chronic hepatitis B patients with advanced fibrosis.","volume":"46","author":"Buster","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R3-18-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-18-20241201","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.","volume":"6","author":"Keeffe","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-18-20241201","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"AsianPacific consensus statement on the management of chronic hepatitis B: a 2005 update.","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"R6-18-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R7-18-20241201","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0168-8278(94)80115-0","article-title":"Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).","volume":"21","author":"Realdi","year":"1994","journal-title":"J Hepatol"},{"key":"R8-18-20241201","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/gut.32.3.294","article-title":"Natural history and prognostic factors for chronic hepatitis type B.","volume":"32","author":"Fattovich","year":"1991","journal-title":"Gut"},{"key":"R9-18-20241201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0676.1989.tb00405.x","article-title":"Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.","volume":"9","author":"Liaw","year":"1989","journal-title":"Liver"},{"key":"R10-18-20241201","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/0016-5085(93)90281-G","article-title":"Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.","volume":"104","author":"Hoofnagle","year":"1993","journal-title":"Gastroenterology"},{"key":"R11-18-20241201","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(95)90401-8","article-title":"Lowdose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.","volume":"109","author":"Perrillo","year":"1995","journal-title":"Gastroenterology"},{"key":"R12-18-20241201","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multicenter United StatesCanadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.","volume":"33","author":"Perrillo","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R13-18-20241201","first-page":"1419","article-title":"Adefovir dipivoxil therapy for lamivudineresistant hepatitis B in pre and postliver transplantation patients.","volume":"38","author":"Schiff","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R14-18-20241201","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/TP.0b013e3181806c8c","article-title":"Entecavir therapy for adefovirresistant hepatitis B virus infection in kidney and liver allograft recipients.","volume":"86","author":"Kamar","year":"2008","journal-title":"Transplantation"},{"key":"R15-18-20241201","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1345\/aph.1E280","article-title":"Tenofovir therapy for lamivudine resistance following liver transplantation.","volume":"38","author":"Neff","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R16-18-20241201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.","volume":"34","author":"Yao","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R17-18-20241201","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","article-title":"Adefovir dipivoxil for waitlisted and postliver transplantation patients with lamivudineresistant hepatitis B: final longterm results.","volume":"13","author":"Schiff","year":"2007","journal-title":"Liver Transpl"},{"key":"R18-18-20241201","first-page":"150","article-title":"AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines.","volume":"13","author":"Lok","year":"2004","journal-title":"in Romanian Rom J Gastroenterol"},{"key":"R19-18-20241201","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.10.018","article-title":"Virologic response and resistance to adefovir in patients with chronic hepatitis B.","volume":"44","author":"Fung","year":"2006","journal-title":"J Hepatol"},{"key":"R20-18-20241201","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","article-title":"Low resistance to adefovir combined with lamivudine: a 3year study of 145 lamivudineresistant hepatitis B patients.","volume":"133","author":"Lampertico","year":"2007","journal-title":"Gastroenterology"},{"key":"R21-18-20241201","first-page":"174","article-title":"Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report.","volume":"45","author":"Kim","year":"2005","journal-title":"in Korean Korean J Gastroenterol"},{"key":"R22-18-20241201","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2893.2005.00704.x","article-title":"Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudineresistant viral mutants.","volume":"13","author":"Liu","year":"2006","journal-title":"J Viral Hepat"},{"key":"R23-18-20241201","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","article-title":"Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAgpositive chronic hepatitis B.","volume":"48","author":"Sung","year":"2008","journal-title":"J Hepatol"},{"key":"R24-18-20241201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/lt.20492","article-title":"Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective.","volume":"11","author":"Terrault","year":"2005","journal-title":"Liver Transpl"},{"key":"R25-18-20241201","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/lt.20217","article-title":"Outcome of liver transplantation for hepatitis B in the United States.","volume":"10","author":"Kim","year":"2004","journal-title":"Liver Transpl"},{"key":"R26-18-20241201","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.tp.0000277289.23677.0a","article-title":"Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the longterm prevention of hepatitis B virus recurrence.","volume":"84","author":"Buti","year":"2007","journal-title":"Transplantation"},{"key":"R27-18-20241201","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/lt.20582","article-title":"Protective antibody levels and dose requirements for IV 5 Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis Binduced end stage liver disease.","volume":"12","author":"Dickson","year":"2006","journal-title":"Liver Transpl"},{"key":"R28-18-20241201","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","article-title":"Lamivudine plus lowdose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.","volume":"132","author":"Gane","year":"2007","journal-title":"Gastroenterology"},{"key":"R29-18-20241201","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.20277","article-title":"Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.","volume":"10","author":"Neff","year":"2004","journal-title":"Liver Transpl"},{"key":"R30-18-20241201","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/lt.20701","article-title":"Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis.","volume":"12","author":"Zheng","year":"2006","journal-title":"Liver Transpl"},{"key":"R31-18-20241201","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/lt.20402","article-title":"Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence.","volume":"11","author":"Marzano","year":"2005","journal-title":"Liver Transpl"},{"key":"R32-18-20241201","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","article-title":"A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as postliver transplantation hepatitis B prophylaxis.","volume":"48","author":"Angus","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R34-18-20241201","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Medical progresshepatitis B virus infection.","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"key":"R35-18-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B.","volume":"45","author":"Kumar","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R36-18-20241201","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2893.1997.00072.x","article-title":"Recombinant interferonalpha therapy for acute hepatitis B: a randomized, doubleblind, placebocontrolled trial.","volume":"4","author":"Tassopoulos","year":"1997","journal-title":"J Viral Hepat"},{"key":"R37-18-20241201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1386-6346(02)00009-8","article-title":"Effectiveness and longterm outcome of lamivudine therapy for acute hepatitis B.","volume":"24","author":"Torii","year":"2002","journal-title":"Hepatol Res"},{"key":"R38-18-20241201","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2893.2004.00504.x","article-title":"The use of lamivudine for patients with acute hepatitis B (a series of cases).","volume":"11","author":"Kondili","year":"2004","journal-title":"J Viral Hepat"},{"key":"R39-18-20241201","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1365-2893.2003.00440.x","article-title":"Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.","volume":"10","author":"van Zonneveld","year":"2003","journal-title":"J Viral Hepat"},{"key":"R40-18-20241201","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3748\/wjg.v10.i6.910","article-title":"Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.","volume":"10","author":"Su","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R41-18-20241201","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3748\/wjg.v9.i7.1501","article-title":"Interruption of HBV intrauterine transmission: a clinical study.","volume":"9","author":"Li","year":"2003","journal-title":"World J Gastroenterol"},{"key":"R42-18-20241201","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2893.2008.01056.x","article-title":"Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, doubleblind, placebocontrolled study.","volume":"16","author":"Xu","year":"2009","journal-title":"J Viral Hepat"},{"key":"R43-18-20241201","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virushepatitis C viruscoinfected patients.","volume":"43","author":"Raimondo","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R44-18-20241201","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1440-1746.2008.05384.x","article-title":"Hepatitis B virushepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment.","volume":"23","author":"Chu","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R45-18-20241201","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0168-8278(03)00470-7","article-title":"Epidemiological and clinical burden of chronic hepatitis B virushepatitis C virus infection. A multicenter Italian study.","volume":"39","author":"Gaeta","year":"2003","journal-title":"J Hepatol"},{"key":"R46-18-20241201","first-page":"2973","article-title":"High doses of alphainterferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.","volume":"96","author":"Villa","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R47-18-20241201","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","article-title":"Peginterferon alfa2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.","volume":"136","author":"Liu","year":"2009","journal-title":"Gastroenterology"},{"key":"R48-18-20241201","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2893.2005.00601.x","article-title":"Treatment of hepatitis D.","volume":"12","author":"Niro","year":"2005","journal-title":"J Viral Hepat"},{"key":"R49-18-20241201","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.","volume":"126","author":"Liaw","year":"2004","journal-title":"Gastroenterology"},{"key":"R50-18-20241201","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Longterm benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"R51-18-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2893.1996.tb00002.x","article-title":"Longterm interferonalpha treatment of children with chronic hepatitis delta: a multicentre study.","volume":"3","author":"Di Marco","year":"1996","journal-title":"J Viral Hepat"},{"key":"R52-18-20241201","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","article-title":"Treatment of chronic hepatitis delta with pegylated interferonalpha2b.","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int"},{"key":"R53-18-20241201","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.","volume":"44","author":"Niro","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R54-18-20241201","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine interferon vs interferon.","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J Viral Hepat"},{"key":"R55-18-20241201","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/521864","article-title":"Longterm outcome in children with chronic hepatitis B: a 24year observation period.","volume":"45","author":"Iorio","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R56-18-20241201","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","article-title":"Clinical trial of lamivudine in children with chronic hepatitis B.","volume":"346","author":"Jonas","year":"2002","journal-title":"N Engl J Med"},{"key":"R57-18-20241201","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.22250","article-title":"Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to 18 years) with chronic hepatitis B.","volume":"47","author":"Jonas","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R58-18-20241201","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0016-5085(98)70318-X","article-title":"Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.","volume":"114","author":"Sokal","year":"1998","journal-title":"Gastroenterology"},{"key":"R59-18-20241201","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2893.2007.00891.x","article-title":"Longterm lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.","volume":"15","author":"Jonas","year":"2008","journal-title":"J Viral Hepat"},{"key":"R60-18-20241201","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1096-9071(20000201)63:2<103::AID-JMV1003>3.0.CO;2-E","article-title":"Prevalence of hepatitis B, hepatitis C, GB virus Chepatitis G and TT viruses in predialysis and hemodialysis patients.","volume":"63","author":"LopezAlcorocho","year":"2001","journal-title":"J Med Virol"},{"key":"R61-18-20241201","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/j.vaccine.2005.02.033","article-title":"A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis.","volume":"23","author":"Liu","year":"2005","journal-title":"Vaccine"},{"key":"R62-18-20241201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3748\/wjg.v11.i3.400","article-title":"Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation.","volume":"11","author":"Lapinski","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R63-18-20241201","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/01.tp.0000178305.39231.a2","article-title":"Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency.","volume":"80","author":"Fontaine","year":"2005","journal-title":"Transplantation"},{"key":"R64-18-20241201","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.1995.27","article-title":"Treatment of hepatitis B virusassociated membranous nephropathy with recombinant alphainterferon.","volume":"47","author":"Lin","year":"1995","journal-title":"Kidney Int"},{"key":"R65-18-20241201","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1523-1755.2005.00591.x","article-title":"Lamivudine in hepatitis Bassociated membranous nephropathy.","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"R66-18-20241201","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0929-6646(08)60054-6","article-title":"Complete remission of nephrotic syndrome of hepatitis B virusassociated membranous glomerulopathy after lamivudine monotherapy.","volume":"106","author":"Chuang","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"R67-18-20241201","first-page":"349","article-title":"Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis. in Chinese.","volume":"16","author":"Li","year":"2008","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R68-18-20241201","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2006.03041.x","article-title":"Metaanalysis: antiviral therapy of hepatitis B virusassociated glomerulonephritis.","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R69-18-20241201","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virusassociated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine (Baltimore)"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22965","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:11:05Z","timestamp":1733058665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":68,"journal-issue":{"issue":"Suppl. 5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22965","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}